According to Gram Research analysis, a plant-derived compound called HMPA prevented kidney inflammation, scarring, and damage in laboratory mice with chronic kidney disease, reducing blood waste markers and uric acid levels. The compound worked by blocking harmful crystal buildup in kidney tubules and suppressing inflammatory genes. However, this is early-stage animal research—human studies are needed before HMPA could be used as a kidney disease treatment.
Researchers discovered that a natural plant compound called HMPA (3-(4-hydroxy-3-methoxyphenyl) propionic acid) may help prevent kidney disease and damage. In a study using specially designed mice, scientists found that HMPA reduced kidney inflammation, prevented scarring, and lowered harmful waste products in the blood. The compound also reduced uric acid levels, which can cause gout and other health problems. These findings suggest HMPA could become a preventive treatment for chronic kidney disease, though human studies are still needed to confirm these results.
Key Statistics
A 2026 research article published in Scientific Reports found that HMPA treatment prevented kidney inflammation signals in specially designed mice within 3 days of disease induction, suggesting early protective effects before major kidney damage occurs.
The study demonstrated that HMPA supplementation reduced blood urea nitrogen and plasma creatinine concentrations in adenine-induced chronic kidney disease mice, indicating improved kidney function and waste filtering.
In a hyperuricemia mouse model, HMPA supplementation reduced blood uric acid concentrations, suggesting potential benefits for preventing gout and uric acid-related kidney damage.
Gene expression analysis in the 2026 study showed that HMPA suppressed multiple inflammation and fibrosis-related genes while supporting protective genes, indicating the compound works through multiple biological pathways.
The Quick Take
- What they studied: Whether a plant-derived compound called HMPA could prevent kidney disease and inflammation in mice with artificially induced chronic kidney disease
- Who participated: Laboratory mice genetically engineered to show kidney inflammation signals; the study used special mice that glow when kidney damage occurs
- Key finding: HMPA treatment prevented kidney inflammation and scarring, reduced blood waste markers (BUN and creatinine), and lowered uric acid levels in diseased mice
- What it means for you: This research is early-stage and only tested in mice, so it’s too soon to use HMPA as a kidney disease treatment in humans. However, it identifies a promising natural compound worth further investigation in clinical trials
The Research Details
Scientists used specially bred laboratory mice that produce a glowing signal in their kidneys when inflammation occurs. They induced kidney disease in these mice using adenine (a chemical compound) and then treated some mice with HMPA while leaving others untreated as a control group. The researchers used imaging technology to watch the glowing signals in real-time, measured kidney function markers in the blood, and examined kidney tissue under microscopes to assess damage and scarring.
The study also tested HMPA in a second mouse model designed to mimic high uric acid levels (hyperuricemia), which is a condition that damages kidneys and causes gout. This allowed researchers to test whether HMPA worked through multiple protective pathways in the body.
The researchers measured several outcomes including inflammation markers, kidney scarring (fibrosis), blood waste products, and uric acid levels to get a complete picture of HMPA’s protective effects.
This research approach is important because it uses real-time imaging to detect kidney damage very early—even before traditional blood tests show problems. This early detection ability could help identify treatments that prevent disease before serious damage occurs. Testing in two different disease models (adenine-induced and uric acid-induced) strengthens confidence that HMPA works through multiple protective mechanisms rather than just one pathway.
The study was published in Scientific Reports, a reputable peer-reviewed journal. The researchers used multiple complementary methods (imaging, blood tests, tissue examination, and gene expression analysis) to confirm their findings, which increases reliability. However, this is animal research only—results in mice don’t always translate to humans. The study lacks specific sample size reporting, which makes it harder to assess statistical power. No human trials have been conducted yet, so safety and effectiveness in people remain unknown.
What the Results Show
HMPA treatment significantly reduced the glowing kidney inflammation signals in mice with adenine-induced kidney disease, suggesting it prevented the inflammatory response. Blood tests showed that HMPA supplementation lowered two key markers of kidney damage: blood urea nitrogen (BUN) and plasma creatinine, both of which accumulate when kidneys fail to filter waste properly.
Microscopic examination of kidney tissue revealed that HMPA prevented fibrosis (scarring), which is a major cause of permanent kidney damage. The compound also prevented the buildup of 2,8-dihydroxyadenine (2,8-DHA) crystals in kidney tubules—these crystals are the direct cause of adenine-induced kidney disease.
Gene expression analysis (examining which genes were turned on or off) confirmed that HMPA suppressed genes involved in inflammation and fibrosis while supporting protective genes. Remarkably, HMPA showed protective effects even when given early in disease development, with no kidney inflammation signals detected just 3 days after disease induction.
In the hyperuricemia model (high uric acid), HMPA supplementation reduced blood uric acid concentrations, suggesting the compound may help prevent gout and uric acid-related kidney damage. The researchers found no evidence that HMPA caused any harmful side effects or additional kidney damage in treated mice. Gene expression profiles showed that HMPA’s protective effects involved multiple biological pathways, not just a single mechanism, which suggests it may work against kidney disease through several different routes simultaneously.
This research builds on previous knowledge that plant compounds with antioxidant properties can protect organs from damage. HMPA is a metabolite of ferulic acid, a compound found in many plants and previously studied for health benefits. The novel contribution here is demonstrating that HMPA specifically prevents both the inflammatory and fibrotic (scarring) aspects of kidney disease, and that it works early in disease development before major damage occurs. The use of real-time imaging to track kidney inflammation is a newer approach that provides advantages over traditional methods.
This study was conducted entirely in laboratory mice, which have different physiology than humans. Results in animal models often don’t translate directly to human medicine. The study doesn’t specify exact sample sizes for each experimental group, making it difficult to assess statistical power. No information is provided about HMPA’s absorption, metabolism, or safety in humans. The adenine model creates kidney disease through a specific mechanism that may not represent all types of chronic kidney disease in humans. Long-term safety and effectiveness data are absent. The study doesn’t compare HMPA to existing kidney disease medications, so its relative effectiveness is unknown.
The Bottom Line
Based on this research, HMPA cannot yet be recommended for human use to prevent or treat kidney disease. The evidence is preliminary and limited to animal studies. People with chronic kidney disease or high uric acid should continue following their doctor’s treatment plans and not self-treat with HMPA supplements. Further research including human clinical trials would be needed before HMPA could be considered for medical use. Confidence level: Low (animal studies only)
Researchers studying kidney disease prevention, pharmaceutical companies developing new treatments, and people with chronic kidney disease or gout should follow this research. However, the general public should not attempt to use HMPA as a treatment until human studies confirm safety and effectiveness. People with existing kidney disease should especially avoid self-treating with untested compounds.
This is very early-stage research. If HMPA moves forward to human trials, it would typically take 5-10 years of additional research before it could potentially become available as a medical treatment. Realistic expectations: No immediate applications for patients, but promising direction for future drug development.
Frequently Asked Questions
Can I take HMPA supplements to prevent kidney disease?
Not yet. HMPA has only been tested in mice, not humans. No human clinical trials have been conducted, so safety and effectiveness in people are unknown. Consult your doctor before taking any new supplements, especially if you have kidney disease.
What is HMPA and where does it come from?
HMPA (3-(4-hydroxy-3-methoxyphenyl) propionic acid) is a natural compound produced in the body when you consume ferulic acid from plants. It’s found in coffee, grains, and other plant foods, but the amounts in normal diet are small.
How does HMPA protect kidneys from damage?
In mice, HMPA worked by preventing crystal buildup in kidney tubules, reducing inflammation, and blocking genes that cause scarring. It appears to work through multiple protective pathways simultaneously, though the exact mechanisms in humans remain unknown.
When will HMPA be available as a kidney disease treatment?
This is very early research. If development continues, human clinical trials would take several years. Realistic timeline: 5-10+ years before HMPA could potentially become a medical treatment, assuming further research is successful.
Does this research apply to all types of kidney disease?
The study tested HMPA in two specific mouse models of kidney disease. Results may not apply to all types of chronic kidney disease in humans. Different kidney diseases have different causes and may respond differently to treatments.
Want to Apply This Research?
- Users interested in kidney health could track kidney function markers (creatinine and BUN levels from blood tests) every 3-6 months, recording the specific numerical values to monitor trends over time
- While HMPA isn’t yet available as a treatment, users can support kidney health by reducing sodium intake, staying hydrated, managing blood pressure, limiting protein consumption, and avoiding excessive uric acid-producing foods (red meat, organ meats, high-fructose beverages)
- Set quarterly reminders for kidney function blood tests if you have risk factors for kidney disease; track results in the app alongside lifestyle factors like diet, exercise, and medication adherence to identify patterns that affect kidney health
This research is preliminary and based entirely on animal studies in mice. HMPA has not been tested in humans and is not approved for medical use. This article is for educational purposes only and should not be considered medical advice. People with chronic kidney disease, high uric acid levels, or other health conditions should consult their healthcare provider before making any changes to their treatment plan or taking new supplements. Do not attempt to self-treat kidney disease with HMPA or other untested compounds. Always follow your doctor’s recommendations for managing kidney health.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.